Examkin

Soru

Zorluk: ZorPharmacologic Interventions

A 68-year-old man is evaluated in the cardiac intensive care unit for acute-onset, severe right knee pain and swelling. He was admitted 2 days ago for a non-ST-segment elevation myocardial infarction (NSTEMI). His medical history is significant for chronic kidney disease stage 4 (baseline serum creatinine 2.4 mg/dL), hypertension, and a history of a bleeding gastric ulcer 1 year ago. His current medications include aspirin, ticagrelor, fondaparinux, metoprolol, and a high-intensity statin.

Vital signs show a temperature of 37.8°C (100.0°F), blood pressure 135/85 mm Hg, and pulse 88/min.

Physical examination reveals a markedly swollen, erythematous, warm, and exquisitely tender right knee. There is a large effusion, and range of motion is severely limited by pain.

Arthrocentesis is performed. Synovial fluid analysis shows a leukocyte count of 45,000/mm³ with 85% neutrophils. Polarized light microscopy reveals strongly negatively birefringent, needle-shaped crystals. Gram stain of the fluid is negative.

Which of the following is the most appropriate pharmacologic intervention for this patient's acute joint condition?

  1. Intra-articular triamcinoloneCevap
  2. B
    Oral indomethacin
  3. C
    Oral colchicine
  4. D
    Intravenous ceftriaxone
  5. E
    Oral allopurinol

Cevap

The correct answer is intra-articular triamcinolone, as it provides localized anti-inflammatory relief without systemic toxicity in a highly comorbid patient.
The correct answer is intra-articular triamcinolone. This patient is experiencing an acute gout flare, evidenced by the classic presentation of acute monoarthritis and synovial fluid analysis revealing negatively birefringent, needle-shaped monosodium urate crystals. The standard first-line pharmacologic interventions for acute gout include NSAIDs, colchicine, and systemic or intra-articular glucocorticoids. However, this patient's complex medical history severely restricts his systemic options. NSAIDs are absolutely contraindicated due to his advanced chronic kidney disease (CKD stage 4), recent acute coronary syndrome (NSTEMI), and history of peptic ulcer disease. Colchicine is inappropriate and potentially dangerous due to his severe renal impairment, which substantially decreases its clearance, and his concurrent use of a high-intensity statin, which increases the risk of severe drug interactions such as fatal neuromyopathy and rhabdomyolysis. Because the flare involves a single, easily accessible joint (the knee), an intra-articular glucocorticoid injection is the safest and most effective targeted pharmacologic intervention. It provides rapid relief of inflammation while minimizing systemic absorption and avoiding exacerbation of his cardiovascular, renal, and gastrointestinal comorbidities.

Adım Adım Çözüm

1
Diagnose the acute condition based on clinical presentation and arthrocentesis findings.
The patient has an acute gout flare, confirmed by the presence of negatively birefringent, needle-shaped crystals in the synovial fluid.
Establishing the correct diagnosis guides the specific pharmacologic treatment pathway and rules out septic arthritis.
2
Evaluate the patient's comorbidities and current medication list for contraindications to standard gout therapies.
The patient has CKD stage 4, a recent NSTEMI, a history of a bleeding ulcer, and takes a high-intensity statin.
First-line systemic therapies for gout (NSAIDs and colchicine) have significant absolute contraindications or severe toxicity risks in these specific settings.
3
Select the safest and most effective targeted therapy for the acute monoarticular flare.
Intra-articular glucocorticoid injection (triamcinolone).
It avoids systemic toxicities, does not interact with the patient's complex medication regimen, and is highly effective for single-joint involvement.

Anahtar Kavram

Management of acute gout in patients with multimorbidity requires careful selection of anti-inflammatory agents; intra-articular glucocorticoids are the safest first-line option when NSAIDs and colchicine are contraindicated by advanced chronic kidney disease, cardiovascular disease, and drug interactions.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru